Open access
Oct 2026
A randomised, open-label, phase II study of tobemstomig combinations in patients with previously untreated advanced clear-cell renal cell carcinoma.
BACKGROUND Immune checkpoint inhibitors combined with vascular endothelial growth factor (VEGF)-targeted tyrosine kinase inhibitors (TKIs) have improved advanced renal cell carcinoma (RCC) outcomes, yet median progression-free survival (PFS) remains <2 years. PATIENTS AND METHODS This randomised (1 : 1 : 1), open-lab...
B. Rini, T. Powles, P. Tomczak et al.
· ESMO Open · 0 citations